Library · Digestive & liver · Treatment of Short Bowel Syndrome
Teduglutide
ALX-0600, Gattex, Revestive
A recombinant analogue of GLP-2, approved by the FDA and EMA for short bowel syndrome in patients needing parenteral support, for adults since 2012 and children one and older since 2019. It promotes intestinal-lining growth and better nutrient absorption; 2024 pediatric data confirm sustained benefit over 96 weeks, and preclinical work hints at use in graft-versus-host disease.
Research score 95/100. Reference only, not a dose.
Boxed warning: Increased risk of malignancies, intestinal obstruction, gallbladder disease, biliary tract disease, and pancreatic disease.
- Gut Health
- Healing
- Anti-inflammatory
- Appetite Stimulation
- Metabolic Enhancement
- US status
- FDA Approved
- Approval
- FDA Approved (2012 for adults, 2019 for pediatrics); EMA Approved (2012)
- Evidence
- Extensive Human Studies, including Phase 3 clinical trials in both adult and pediatric populations with short bowel syndrome. It is an established therapy recommended in international clinical guidelines for malabsorption.
- Research score
- 95 / 100
- Indication
- Short Bowel Syndrome
- Origin
- USA
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
A single amino-acid substitution extends its half-life versus native GLP-2; it binds GLP-2 receptors on gut cells to raise crypt-cell growth, reduce cell death, boost blood flow via nitric oxide, and expand villus height and absorptive surface, while raising nutrient transporters and digestive enzyme secretion.
Safety file
Generally well tolerated with monitoring; requires a formal risk management program due to serious potential risks.
- Abdominal pain
- Nausea
- Injection site reactions
- Upper respiratory tract infections
- Fluid overload
- Gastrointestinal stoma complications
- Catheter sepsis
- Urinary tract infections